Abstract:Cancer-associated fibroblasts (CAFs) are a prominent component of the tumor microenvironment (TME) and are known for their role in supporting tumor growth and progression through interactions with cancer cells and other stromal elements. Liver metastatic CAFs (lmCAFs), in particular, play an important role in establishing the secondary niche that facilitates tumor metastasis. Reprogramming the stroma, particularly targeting the pro-tumorigenic functions of lmCAFs, has emerged as a promising therapeutic intervention to disrupt the supportive environment tumors rely on for progression. An initial drug screen of FDA-approved oncology therapies was conducted on patient-derived colorectal cancer (CRC) CAFs and tumor organoids (PDTOs) to identify compounds that may be re-purposed as stroma targeting agents. All-trans retinoic acid (ATRA) was shown to specifically inhibit the proliferation of CAFs without affecting CRC-PDTOs. ATRA is an active metabolite of Vitamin A that exerts its canonical biological effects by binding to nuclear retinoic acid receptors (RAR). The differential RAR expression in multiple CAFs and PDTOs was confirmed with bulk RNA sequencing, with higher expression found in the CAF lines. Subsequent analysis included the qPCR assessment of glycolysis enzyme levels, CAF activation markers, and ATRA signaling in lmCAFs following treatment with ATRA for 5 days. Protein expression of key components of the TGF-b signaling pathway, including SMAD 2/3, Akt, and b-catenin, were also analyzed. Treatment of lmCAFs with ATRA induced expression of RARb and ALDH1A1, biomarkers associated with ATRA signaling pathways. In one patient-derived CAF line, ATRA treatment exhibited a decrease in CAF activation markers (e.g. aSMA) and glycolytic enzymes (e.g. lactate dehydrogenase). On the other hand, another CAF line showed increased fibroblast activation and a shift away from metabolic dependency on glycolysis upon ATRA treatment. Additionally, ATRA targeted TGF-b signaling through the pSMAD 2/3 and Akt pathways, highlighting the multifaceted impact on CAF function and heterogeneity. ATRA effectively reprograms some CAFs by inhibiting their proliferation and altering key signaling pathways, thereby disrupting the pro-tumorigenic environment of the TME. The results of this study suggest that ATRA holds potential as a therapeutic strategy to target and reprogram the CAFs within the permissive stromal components essential for tumor progression. Citation Format: Brandon Choi, Yuyuan Zhou, Seungil Kim, Shannon M. Mumenthaler. Targeting colorectal cancer-associated fibroblasts with all-trans retinoic acid to reprogram the tumor microenvironment [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer; 2024 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(22_Suppl) nr C031.

Abstract 1142: E2F1 Impairs All-Trans Retinoic Acid-Induced Osteogenic Differentiation of Osteosarcoma by Promoting Ubiquitination-Mediated Degradation of RARa

The E3 Ubiquitin Protein Ligase MDM2 Dictates All- Trans Retinoic Acid-Induced Osteoblastic Differentiation of Osteosarcoma Cells by Modulating the Degradation of RARα

All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages.

Data from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-<i>Trans</i>-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis

Inhibition of all-trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells.

Small Ubiquitin‐related Modifier‐1 Modification Regulates All‐trans‐retinoic Acid‐induced Differentiation Via Stabilization of Retinoic Acid Receptor Α

Oridonin Upregulates All-Trans Retinoic Acid Receptor Alpha And Induces Differentiation Of Nb4 Cells Though Nf-Kb Pathway

Abstract 4538: Small Ubiquitin-Related Modifier-1 (SUMO-1) Modification of Retinoic Acid Receptor Α (rarα) Regulates Its Nuclear Localization and Metabolic Stability

The HER2 Inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by Activating MEK/ERK Mediated RARα/STAT1 Axis

Inhibition of M2-like Macrophages by All-Trans Retinoic Acid Prevents Cancer Initiation and Stemness in Osteosarcoma Cells.

A Genomic and Proteomic Research for the Regulatory Networks of Atra-Induced Differentiation of Acute Promyelocytic Leukemia Cells

Combined staurosporine and retinoic acid induces differentiation in retinoic acid resistant acute promyelocytic leukemia cell lines

A novel all-trans retinoic acid derivative regulates cell cycle and differentiation of myelodysplastic syndrome cells by USO1

Enzastaurin Enhances ATRA-induced Differentiation of Acute Myeloid Leukemia Cells.

Comparative Proteomic Analysis of All-Trans-retinoic Acid Treatment Reveals Systematic Posttranscriptional Control Mechanisms in Acute Promyelocytic Leukemia

Involvement of miR-769-5p/Retinoic Acid Receptor Responder 1 Axis in the Progression of Osteosarcoma: Characterization of Potential Therapeutic Targets

Abstract C031: Targeting colorectal cancer-associated fibroblasts with all-trans retinoic acid to reprogram the tumor microenvironment

The Ubiquitin-Proteasome Pathway Plays Essential Roles In Atra-Induced Leukemia Cells G(0)/G(1) Phase Arrest And Transition Into Granulocytic Differentiation

Restoration Of Ccaat Enhancer Binding Protein Alpha P42 Overcomes Myeloid Differentiation Block And All-Trans Retinoic Acid Resistance In Human Acute Promyelocytic Leukemia Nb4-R1 Cells

Ubiquitinated or Sumoylated Retinoic Acid Receptor Alpha Determines Its Characteristic and Interacting Model with Retinoid X Receptor Alpha in Gastric and Breast Cancer Cells.

Combination of Ethacrynic Acid and ATRA Triggers Differentiation and/or Apoptosis of Acute Myeloid Leukemia Cells through ROS